Genomic Frontiers: Navigating the Valuation Reset in Genetic Medicine
The genomic sector enters a phase of intense consolidation as the 'free money' era for biotech expires. Discover why clinical roadmaps and patent moats are the new benchmarks for survival.
By Sneha Patel2026-03-02T18:30:00.000Z